
Allogene Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Allogene Therapeutics develops allogeneic (off-the-shelf) CAR T cell therapies derived from healthy donor cells, aiming to treat cancer patients without the need for patient-specific cell manufacturing used in traditional CAR T approaches.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Parker Geoffrey M.CHIEF FINANCIAL OFFICER | Sell | $49K | 36,342at $1.34 | Oct 21, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ALLO activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.